KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Liabilities and Shareholders Equity (2016 - 2025)

TherapeuticsMD's Liabilities and Shareholders Equity history spans 16 years, with the latest figure at $37.7 million for Q4 2025.

  • For Q4 2025, Liabilities and Shareholders Equity fell 3.0% year-over-year to $37.7 million; the TTM value through Dec 2025 reached $153.1 million, down 4.68%, while the annual FY2025 figure was $37.7 million, 3.0% down from the prior year.
  • Liabilities and Shareholders Equity reached $37.7 million in Q4 2025 per TXMD's latest filing, down from $38.7 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $239.3 million in Q1 2021 to a low of $37.7 million in Q4 2025.
  • Average Liabilities and Shareholders Equity over 5 years is $92.7 million, with a median of $52.1 million recorded in 2023.
  • Peak YoY movement for Liabilities and Shareholders Equity: grew 18.24% in 2021, then crashed 63.28% in 2023.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $169.5 million in 2021, then crashed by 46.62% to $90.5 million in 2022, then crashed by 52.12% to $43.3 million in 2023, then fell by 10.36% to $38.8 million in 2024, then fell by 3.0% to $37.7 million in 2025.
  • Per Business Quant, the three most recent readings for TXMD's Liabilities and Shareholders Equity are $37.7 million (Q4 2025), $38.7 million (Q3 2025), and $38.5 million (Q2 2025).